Fig. 6

Targeting shisa3-regulated signaling restored EGFR-TKI sensitivity. a. Growth curves in the PC9/ER-control and PC9/ER-shisa3 models with control (1% Tween 80 in PBS), gefitinib (60 mg/kg/d) or osimertinib (25 mg/kg/d) treatments at the indicated time points. Data are presented as the means ± SDs; n = 5. b. Representative xenograft images of PC9/ER-control and PC9/ER-shisa3 tumors with or without gefitinib and osimertinib treatments. c. Histogram of tumor weights in PC9/ER-control and PC9/ER-shisa3 tumors with or without gefitinib and osimertinib treatment. d. Growth curves in the PC9/ER models with gefitinib (45 mg/kg/d), BEZ235 (40 mg/kg/d), PD0332991 (75 mg/kg/d), or a 3-drug combination treatment at the indicated time points. Data are presented as the means ± SDs; n = 4. e. Representative xenograft images of PC9/ER tumors with the indicated treatments. f. Histogram of tumor weights in PC9/ER tumors with the indicated treatments. c, d and f: *p < 0.05; **p < 0.001